Relationship of Selected Adipokines with Markers of Vascular Damage in Patients with Type 2 Diabetes
Jazyk angličtina Země Spojené státy americké Médium print-electronic
Typ dokumentu časopisecké články, práce podpořená grantem
PubMed
29717906
DOI
10.1089/met.2017.0179
Knihovny.cz E-zdroje
- Klíčová slova
- adipokines, arterial stiffness, type 2 diabetes,
- MeSH
- adipokiny krev MeSH
- adiponektin krev MeSH
- biologické markery krev MeSH
- diabetes mellitus 2. typu krev komplikace MeSH
- diabetické angiopatie krev MeSH
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- metabolický syndrom MeSH
- proteiny vázající mastné kyseliny krev MeSH
- průřezové studie MeSH
- rizikové faktory MeSH
- tuhost cévní stěny MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- Názvy látek
- adipokiny MeSH
- adiponektin MeSH
- ADIPOQ protein, human MeSH Prohlížeč
- biologické markery MeSH
- FABP4 protein, human MeSH Prohlížeč
- proteiny vázající mastné kyseliny MeSH
BACKGROUND: In this study we compared levels of selected adipokines between patients with type 2 diabetes (T2D) and healthy individuals and we determined their relationship with early vascular damage markers. METHODS: Seventy-seven subjects: 56 patients with T2D (34 men and 22 women) and 21 healthy controls (8 men and 13 women) were examined in this cross-sectional study. Selected adipokines [adiponectin, adipocyte fatty acid-binding protein (A-FABP), fibroblast growth factor 21 (FGF-21), C1q/TNF-related protein 9 (CTRP-9), and allograft inflammatory factor-1 (AIF-1)] with possible cardiovascular impact were measured in all participants. To identify markers of vascular damage von Willebrand factor (vWF), plasminogen activator inhibitor-1 (PAI-1) and arterial stiffness parameters were examined in all the subjects. RESULTS: When compared with healthy controls, T2D had significantly higher levels of A-FABP [50.0 (38.1-68.6) vs. 28.6 (23.6-32.9) ng/mL, P < 0.0001] and lower levels of adiponectin [5.9 (4.3-9.0) vs. 11.3 (8.7-14.8) μg/mL, P < 0.0001]. Differences in other adipokines were not statistically significant. Adiponectin level correlated negatively with vWF levels (ρ = -0.29, P < 0.05) and PAI-1 (ρ = -0.36, P < 0.05) and A-FABP positively with vWF (ρ = 0.61, P < 0.05) and PAI-1 (ρ = 0.47, P < 0.05) and augmentation index (ρ = 0.26, P < 0.05). Multivariate regression analysis showed independent association between A-FABP and vWF (b = 0.24, P < 0.05). CONCLUSIONS: Patients with T2D have significantly higher levels of A-FABP and lower levels of adiponectin. These adipokines correlate with indicators of vascular damage and could contribute to cardiovascular risk in patients with T2D. A-FABP may participate in direct endothelium damage.
Department of Clinical Biochemistry University Hospital Olomouc Olomouc Czech Republic
Faculty of Medicine and Dentistry Palacky University Olomouc Olomouc Czech Republic
Citace poskytuje Crossref.org
Adipocytokines in Graves' orbitopathy and the effect of high-dose corticosteroids
Role of Adipose Tissue in Inflammatory Bowel Disease
Circulating levels of selected adipokines in women with gestational diabetes and type 2 diabetes
